Albumedix extends research collaboration with Cobra Biologics

Albumedix ('Albumedix') an emerging leader in the enablement of advanced therapies and recognized global leader in recombinant human albumin (rHA) has today announced an extension to its research collaboration with Cobra Biologics, the gene therapy division of Cognate BioServices, a Charles River Laboratories International, Inc. company. The research collaboration focuses on process optimization and stability enhancement in scale-up manufacturing of AAV and lentiviral vectors through through Albumedix' proprietary recombinant human albumin-based product.

Additionally, the collaboration aims to advance both up-stream and down-stream processing of AAV and lentiviral vector manufacturing, including formulation development for long-term stability.

Read the press release in full.